Status note Pivotal Phase 2B/3 MIRACLE trial (MB-108) in R/R AML. Phase 1B/2 STS lung mets trials completed. Physician-sponsored Phase 1B/2 in 3rd-line pancreatic cancer planned for 2026. FDA Fast Track and Orphan Drug designated for AML and soft tissue sarcoma.
WP1066
Phase 2 · ActiveModality: small molecule
Target p-STAT3
Partnerships Northwestern University (externally funded physician-sponsored trial)
Indications
Glioblastoma (with radiation)(Phase 2)
Status note Externally funded Phase 1B/2 trial of oral formulation in combination with radiation in glioblastoma actively recruiting in adults; pediatric trial in planning. Prior Emory physician-sponsored Phase 1 in pediatric brain tumors concluded Feb 2023.
WP1122
Stage not disclosed · ActiveModality: small molecule
Target glycolysis
Partnerships University of Texas MD Anderson Cancer Center (license)
Indications
not disclosed(Stage not disclosed)
Status note Recommended Phase 2 dose established to potentially enable future externally funded oncology and virology trials; no active trial disclosed.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.